FindTrial
Sign In

Study on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis Imperfecta

Study on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis Imperfecta

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-005275-42-IT
Enrollment
Unknown
Registered
2008-01-23
Start date
2005-03-21
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteogenesis Imperfecta MedDRA version: 6.1 Level: SOC Classification code 10010331

Interventions

Trade Name: GENOTROPIN*1TBF 5,3MG (16UI) Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Somatropin CAS Number: 12629-01-5 Concentration unit: mg milligram(s) C

Sponsors

AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026